Molecular and Cellular Biology, April 1999, p. 2465-2474, Vol. 19, No. 4
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Terry Fox Molecular Oncology Group,
Received 24 August 1998/Returned for modification 28 October
1998/Accepted 4 January 1999
The interferon regulatory factor 3 (IRF-3) gene encodes a 55-kDa
protein which is expressed constitutively in all tissues. In
unstimulated cells, IRF-3 is present in an inactive cytoplasmic form;
following Sendai virus infection, IRF-3 is posttranslationally modified
by protein phosphorylation at multiple serine and threonine residues located in the carboxy terminus. Virus-induced phosphorylation of IRF-3 leads to cytoplasmic to nuclear translocation of
phosphorylated IRF-3, association with the transcriptional coactivator
CBP/p300, and stimulation of DNA binding and transcriptional activities of virus-inducible genes. Using yeast and mammalian one-hybrid analysis, we now demonstrate that an extended, atypical transactivation domain is located in the C terminus of IRF-3 between amino acids (aa)
134 and 394. We also show that the C-terminal domain of IRF-3 located
between aa 380 and 427 participates in the autoinhibition of IRF-3
activity via an intramolecular association with the N-terminal region
between aa 98 and 240. After Sendai virus infection, an intermolecular
association between IRF-3 proteins is detected, demonstrating a
virus-dependent formation of IRF-3 homodimers; this interaction is
also observed in the absence of virus infection with a constitutively
activated form of IRF-3. Substitution of the C-terminal Ser-Thr
phosphorylation sites with the phosphomimetic Asp in the region
ISNSHPLSLTSDQ between amino acids 395 and 407 [IRF-3(5D)], but not
the adjacent S385 and S386 residues, generates a constitutively
activated DNA binding form of IRF-3. In contrast, substitution of S385
and S386 with either Ala or Asp inhibits both DNA binding and
transactivation activities of the IRF-3(5D) protein. These studies
thus define the transactivation domain of IRF-3, two domains that
participate in the autoinhibition of IRF-3 activity, and the regulatory
phosphorylation sites controlling IRF-3 dimer formation, DNA binding
activity, and association with the CBP/p300 coactivator.
*
Corresponding author. Mailing address: Lady Davis
Institute for Medical Research, 3755 Cote Ste. Catherine, Montreal,
Quebec, Canada H3T 1E2. Phone: (514) 340-8222, ext. 4509. Fax: (514)
340-7576. E-mail: mdli{at}musica.mcgill.ca.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|